Exclusive: GLOBEIMMUNE INC (OTCMKTS:GBIM) Institutional Investors 2016 Q2 Sentiment

November 18, 2016 - By Ellis Scott   ·   0 Comments

Exclusive: GLOBEIMMUNE INC (OTCMKTS:GBIM) Institutional Investors  2016 Q2 Sentiment

Sentiment for GLOBEIMMUNE INC (OTCMKTS:GBIM)

GLOBEIMMUNE INC (OTCMKTS:GBIM) institutional sentiment decreased to 0 in Q2 2016. Its down -0.67, from 0.67 in 2016Q1. The ratio has worsened, as 4 hedge funds increased and opened new equity positions, while 6 trimmed and sold equity positions in GLOBEIMMUNE INC. The hedge funds in our partner’s database now hold: 701,163 shares, down from 709,248 shares in 2016Q1. Also, the number of hedge funds holding GLOBEIMMUNE INC in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 4 Reduced: 2 Increased: 2 New Position: 2.

GlobeImmune, Inc. is a biopharmaceutical company. The company has a market cap of $3.22 million. The Firm is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. It currently has negative earnings. The Company’s segment is the business of developing and commercializing various biopharmaceutical products.

About 438,981 shares traded hands or 973.20% up from the average. GlobeImmune Inc (OTCMKTS:GBIM) has declined 65.42% since April 18, 2016 and is downtrending. It has underperformed by 69.85% the S&P500.

According to Zacks Investment Research, “GlobeImmune, Inc. is a biopharmaceutical company. It is focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen (R) platform. The Company’s products under development includes GI-5005, a product for the treatment of chronic hepatitis C infection; and GI-4000 for pancreas, non-small cell lung, colorectal, and other cancers. GlobeImmune, Inc. is based in Louisville, Colorado.”

Bvf Inc Il holds 0.27% of its portfolio in GlobeImmune Inc for 657,653 shares. Two Sigma Securities Llc owns 16,000 shares or 0.02% of their US portfolio. Moreover, Bank Of America Corp De has 0% invested in the company for 1,000 shares. The California-based Blackrock Fund Advisors has invested 0% in the stock. Citigroup Inc, a New York-based fund reported 500 shares.#img1#

GBIM Company Profile

GlobeImmune, Inc., incorporated on June 5, 2002, is a biopharmaceutical company. The Firm is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Company’s segment is the business of developing and commercializing various biopharmaceutical products. The Firm has approximately three Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The Company’s infectious disease product candidates include GS-4774, which is in Phase II for the treatment of chronic hepatitis B infection; GI-19000, which is in the preclinical stage of development for the treatment of tuberculosis; GI-2010, which is in the preclinical stage of development for the treatment of Human immunodeficiency virus (HIV), and GI-18000, which is in the preclinical stage of development for the treatment of Chronic hepatitis D infection. The Company’s oncology product candidates include GI-6207, which is in Phase II for the treatment of medullary thyroid cancer; GI-6301, which is in Phase II for the treatment of chordoma, and GI-4000, which is in Phase IIb for the treatment of Resected pancreas cancer, and in Phase II for the treatment of Non-small cell lung cancer and colorectal cancer.

More important recent GlobeImmune Inc (OTCMKTS:GBIM) news were published by: Quotes.Wsj.com which released: “GlobeImmune Inc. GBIM (US: OTC)” on September 15, 2012, also Denverpost.com published article titled: “With half-dozen employees, GlobeImmune weighs sale”, Reuters.com published: “BRIEF-GlobeImmune announces updates” on November 17, 2016. More interesting news about GlobeImmune Inc (OTCMKTS:GBIM) was released by: Fiercebiotech.com and their article: “GlobeImmune, Inc. Reports Positive Results for Two Therapeutic Vaccines, GI …” with publication date: June 01, 2011.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Ellis Scott


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>